AQST

Aquestive Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-04

Figures on this page computed 2026-11-07 11:22 UTC

Last close

3.66USD

Market data, 2026-11-05

AQST: weekly closes from 6.04 on 2025-11-07 to 3.66 on 2026-11-05, a move of -39.4%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-05

Over that span: -39.4%

Except where said otherwise: 10-K for 2025, filed 2026-03-04

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
The filing itself
-188.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
-119.0%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.16 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.83x

1.81x

1.98x

0.94x

0.84x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-05

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-04

Sales0.83x
Its own average over 10 years, 53.6M.
Profit1.81x
Its own average over 10 years, -46.3M.
Free cash flow1.98x
Its own average over 10 years, -26.8M.
Debt0.94x
Its own average over 8 years, 45.5M.
Price0.84x
Its own average over 9 years, 4. Market data, 2026-11-05

Free cash flow is furthest from its own average, at 1.98 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-12-31	100.0	100.0
2017-12-31	129.2	n/a
2018-12-31	130.2	n/a
2019-12-31	101.6	n/a
2020-12-31	88.5	137.4
2021-12-31	98.2	155.4
2022-12-31	92.1	198.9
2023-12-31	97.7	250.0
2024-12-31	111.2	354.0
2025-12-31	86.0	436.4

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001398733-26-000018
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001398733-26-000018
Reported in: USD

The filing itself

Figures behind the shape

Growth

-0.6%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate-0.6%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
One-year change in net income-89.8%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Returns on capital

-52.2%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
The filing itself
Return on equityn/mnegative equity
Negative equity.
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
The filing itself
Return on assets-52.2%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
The filing itself

Margins

58.4%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross margin58.4%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Operating margin-159.5%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Net margin-188.1%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Free cash flow margin-119.0%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself

Price

8.7x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
Price to bookn/a10-Q for 2025, filed 2026-11-03
We do not hold this figure for this company, so there is nothing to place.
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001398733-26-000074
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-11-03
- computed
- 10-K for 2025, filed 2026-03-04
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-03-04
The filing itself
Price to sales ratio8.7x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself

Safety

3.14

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-Q for 2025, filed 2026-11-03
The filing itself
Current ratio3.1410-Q for 2025, filed 2026-11-03
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001398733-26-000074
Reported in
USD
- 10-Q for 2025, filed 2026-11-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Altman Z-Score-3.13
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-06
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001398733-26-000018
Reported in
USD
- 10-K for 2025, filed 2026-03-04
- Computed from the 10-K for 2025, filed 2026-03-04
- 10-K for 2025, filed 2026-03-04
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.